1 |
Hsu, J. C. (1984). Constrained simultaneous confidence intervals for multiple comparisons with the best, The Annals of Statistics, 12, 1136-1144
DOI
|
2 |
Chow, S. C. and Liu, J. P. (2000). Design and Analysis of Bioevailability and Bioequivalence Studies, 2nd edition, Marcel Dekker, New York
|
3 |
Chow, S. C. and Shao, J. (2002). Statistics in Drug Research: Methodologies and Recent Developments, Marcel Dekker, New York
|
4 |
FDA (1992). Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland
|
5 |
권광옥, 김옥희, 김종국, 김주일, 배균섭, 사홍기, 이용복, 이화정, 최선옥 (2006). <생물학적 동등성의 이해>, 신일상사
|
6 |
Berger, R. L. and Hsu, J. C. (1996). Bioequivalence trials, intersection union-tests and equivalence confidence sets (with discussion), Statistical Science, 11, 283-319
DOI
ScienceOn
|
7 |
식품의약품안전청 (2005). 고시 제 2005-31호 생물학적 동등성시험기준
|
8 |
ICH (1998). Statistical principles for clinical trials, Tripartite International Conference on Harmonization Guideline, E9
|
9 |
Lehmann, E. L. (1986). Testing Statistical Hypotheses, 2nd edition, John Wiley & Sons, New York
|
10 |
Liu, H. K. (1990). Confidence intervals in bioequivalence assessment, In Proceedings of the Biopharmaceutical Section of the American Statistical Association, 51-54
|
11 |
Westlake, W. J. (1976). Symmetric confidence intervals for bioequivalence trials, Biometrics, 32, 741-744
DOI
ScienceOn
|